Intravitreal aflibercept: its role in treatment of neovascular age-related macular degeneration

References

• Magnitude and causes of visual impairment [fact sheet no. 282]. [cited 2016 May 17]. Available from: http://www.who.int/mediacentre/factsheets/fs282/en/
   Google Scholar
• Mitchell P, Smith W, Attebo K, et al. Prevalence of age-related maculopathy in Australia. The Blue Mountains Eye Study. Ophthalmology. 1995;102:1450–1460.
   PubMed Web of Science ®Google Scholar
• Klaver CC, Wolfs RC, Vingerling JR, et al. Age-specific prevalence and causes of blindness and visual impairment in an older population; the Rotterdam study. Arch Ophthalmol. 1998;116:653–658.
   PubMed Web of Science ®Google Scholar
• Klaver CC, Assink JJ, van Leeuwen R, et al. Incidence and progression rates of age-related maculopathy: the Rotterdam study. Invest Ophthalmol Vis Sci. 2001;42:2237–2241.
   PubMed Web of Science ®Google Scholar
• Pascolini D, Mariotti SP, Pokharel GP, et al. 2002 global update of available data on visual impairment: a compilation of population-based prevalence studies. Ophthalmic Epidemiol. 2004;11:67–115.
   PubMed Web of Science ®Google Scholar
• Kawasaki R, Yasuda M, Song SJ, et al. The prevalence of age-related macular degeneration in Asians: a systematic review and meta-analysis. Ophthalmology. 2010;117:921–927.
   PubMed Web of Science ®Google Scholar
• Wong WL, Su X, Li X, et al. Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis. Lancet Global Health. 2014;2:e106–16.
   PubMed Web of Science ®Google Scholar
• The Royal College of Ophthalmologists. Age-related macular degeneration: guidelines for management. Sep 2013 [cited 2016 May 25]. Available from: https://www.rcophth.ac.uk/wp-content/uploads/2014/12/2013-SCI-318-RCOphth-AMD-Guidelines-Sept-2013-FINAL-2.pdf
   Google Scholar
• Bird AC, Bressler NM, Bressler SB, et al. An international classification and grading system for age-related maculopathy and age-related macular degeneration. The International ARM Epidemiological Study Group. Surv Ophthalmol. 1995;39:367–374.
   PubMed Web of Science ®Google Scholar
• Klein R, Klein BE, Knudtson MD, et al. Prevalence of age-related macular degeneration in 4 racial/ethnic groups in the multi-ethnic study of atherosclerosis. Ophthalmology. 2006;113:373–380.
   PubMed Web of Science ®Google Scholar
• Klein R, Klein B, Linton K. Prevalence of age-related maculopathy. The Beaver Dam eye study. Ophthalmology. 1992;99:933–943.
   PubMed Web of Science ®Google Scholar
• Vingerling J, Dielemans I, Hofman A, et al. The prevalence of age-related maculopathy in the Rotterdam Study. Ophthalmology. 1995;102:205–210.
   PubMed Web of Science ®Google Scholar
• VanNewkirk M, Nanjan M, Wang J, et al. The prevalence of age-related maculopathy: the visual impairment project. Ophthalmology. 2000;107:1593–1600.
   PubMed Web of Science ®Google Scholar
• Williams MA, Craig D, Passmore P, et al. Retinal drusen: harbingers of age, safe havens for trouble. Age Ageing. 2009;38:648–654.
   PubMed Web of Science ®Google Scholar
• Luthert PJ. Pathogenesis of age-related macular degeneration. Diagn Histopathol. 2011;17:10–16.
   Google Scholar
• Klein R, Klein BE, Knudtson MD, et al. Fifteen-year cumulative incidence of age-related macular degeneration: the Beaver Dam eye study. Ophthalmology. 2007;114:253–262.
   PubMed Web of Science ®Google Scholar
• Chopdar A, Chakravarthy U, Verma D. Age related macular degeneration. BMJ (Clinical Research Ed). 2003;326:485–488.
   PubMed Web of Science ®Google Scholar
• Jung J, Chen C, Mrejen S, et al. The incidence of neovascular subtypes in newly diagnosed neovascular age-related macular degeneration. Am J Ophthalmol. 2014;158769–79.e2.
   PubMed Web of Science ®Google Scholar
• Guyer D, Yannuzzi L, Slakter J, et al. Classification of choroidal neovascularization by digital indocyanine green videoangiography. Ophthalmology. 1996;103:2054–2060.
   PubMed Web of Science ®Google Scholar
• Ciardella AP, Donsoff IM, Huang SJ, et al. Polypoidal choroidal vasculopathy. Surv Ophthalmol. 2004;49:25–37.
   PubMed Web of Science ®Google Scholar
• Bloch SB, Larsen M, Munch IC. Incidence of legal blindness from age-related macular degeneration in Denmark: year 2000 to 2010. Am J Ophthalmol. 2012 Feb;153:209–213.
   PubMed Web of Science ®Google Scholar
• Leung DW, Cachianes G, Kuang WJ, et al. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science. 1989;246:1306–1309.
   PubMed Web of Science ®Google Scholar
• Alon T, Hemo I, Itin A, et al. Vascular endothelial growth factor acts as a survival factor for newly formed retinal vessels and has implications for retinopathy of prematurity. Nat Med. 1995;1:1024–1028.
   PubMed Web of Science ®Google Scholar
• Asahara T, Takahashi T, Masuda H, et al. VEGF contributes to postnatal neovascularization by mobilizing bone marrow-derived endothelial progenitor cells. EMBO J. 1999;18:3964–3972.
   PubMed Web of Science ®Google Scholar
• Roberts WG, Palade GE. Increased microvascular permeability and endothelial fenestration induced by vascular endothelial growth factor. J Cell Sci. 1995;108:2369–2379.
   PubMed Web of Science ®Google Scholar
• Monsky WL, Fukumara D, Gohongi T, et al. Augmentation of transvascular transport of macromolecules and nanoparticles in tumors using vascular endothelial growth factor. Cancer Res. 1999;59:4129–4135.
   PubMed Web of Science ®Google Scholar
• Campa C, Costagliola C, Incorvaia C, et al. Inflammatory mediators and angiogenic factors in choroidal neovascularization: pathogenetic interactions and therapeutic implications. Mediators Inflamm. 2010;2010:1–14.
   Google Scholar
• Vinores SA, Xiao WH, Aslam S, et al. Implication of the hypoxia response element of the VEGF promoter in mouse models of retinal and choroidal neovascularization, but not retinal vascular development. J Cell Physiol. 2006;206:749–758.
   PubMed Web of Science ®Google Scholar
• Tolentino MJ, Brucker AJ, Fosnot J, et al. Intravitreal injection of vascular endothelial growth factor small interfering RNA inhibits growth and leakage in a nonhuman primate, laser-induced model of choroidal neovascularization. Retina. 2004;24:132–138.
   PubMed Web of Science ®Google Scholar
• Stewart MW. The expanding role of vascular endothelial growth factor inhibitors in ophthalmology. Mayo Clin Proc. 2012;87:77–88.
   PubMed Web of Science ®Google Scholar
• Macular Photocoagulation Study Group. Argon laser photocoagulation for neovascular maculopathy. Five-year results from randomized clinical trials. Arch Ophthalmol. 1991;109:1109–1114.
   PubMed Web of Science ®Google Scholar
• Macular Photocoagulation Study Group. Recurrent choroidal neovascularisation after argon laser photocoagulation for neovascular maculopathy. Arch Ophthalmol. 1986;104:503–512.
   PubMed Web of Science ®Google Scholar
• The Moorfields Macular Study Group. Treatment of senile disciform macular degeneration: a single-blind randomised trial by argon laser photocoagulation. Br J Ophthalmol. 1982;66:745–753.
   PubMed Web of Science ®Google Scholar
• Newman DK. Photodynamic therapy: current role in the treatment of chorioretinal conditions. Eye (Lond). 2016;30:202–210.
   PubMed Web of Science ®Google Scholar
• Miller JW, Schmidt-Erfurth U, Sickenberg M, et al. Photodynamic therapy with verteporfin for choroidal neovascularization caused by age-related macular degeneration: results of a single treatment in a phase 1 and 2 study. Arch Ophthalmol. 1999;117:1161–1173.
   PubMedGoogle Scholar
• Treatment of age-related macular degeneration with photodynamic therapy (TAP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials – TAP report. Arch Ophthalmol. 1999;117:1329–1345.
   PubMed Web of Science ®Google Scholar
• Verteporfin in Photodynamic Therapy (VIP) Study Group. Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization. — Verteporfin in photodynamic therapy report 2. Am J Ophthalmol. 2001;131:541–560.
   PubMed Web of Science ®Google Scholar
• Blinder KJ, Bradley S, Bressler NM, et al., Treatment of age-related macular degeneration with photodynamic therapy study group; verteporfin in photodynamic therapy study group. Effect of lesion size, visual acuity, and lesion composition on visual acuity change with and without verteporfin therapy for choroidal neovascularization secondary to age-related macular degeneration: TAP and VIP report no. 1. Am J Ophthalmol. 2003;136:407–418.
   PubMed Web of Science ®Google Scholar
• Azab M, Benchaboune M, Blinder KJ, et al., Treatment of age-related macular degeneration with photodynamic therapy (TAP) study group; verteporfin in photodynamic therapy (VIP) study group. Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: meta-analysis of 2-year safety results in three randomized clinical trials: treatment of age-related macular degeneration with photodynamic therapy and verteporfin in photodynamic therapy study report no. 4. Retina. 2004;24:1–12.
   PubMed Web of Science ®Google Scholar
• Koh A, Lee WK, Chen LJ, et al. EVEREST study: efficacy and safety of verteporfin photodynamic therapy in combination with ranibizumab or alone versus ranibizumab monotherapy in patients with symptomatic macular polypoidal choroidal vasculopathy. Retina. 2012;32:1453–1464.
   PubMed Web of Science ®Google Scholar
• Wang Y, Wang VM, Chan CC. The role of anti-inflammatory agents in age-related macular degeneration (AMD) treatment. Eye (Lond). 2011;25:127–139.
   PubMed Web of Science ®Google Scholar
• The Anecortave Acetate Clinical Study Group. Anecortave acetate as monotherapy for treatment of subfoveal neovascularisation in age-related macular degeneration – twelve-month clinical outcomes. Ophthalmology. 2003;110:2372–2383.
   PubMed Web of Science ®Google Scholar
• Gillies MC, Simpson JM, Luo W, et al. A randomised clinical trial of a single dose of intravitreal triamcinolone acetonide for neovascular age-related macular degeneration. One-year results. Arch Ophthalmol. 2003;121:667–673.
   PubMed Web of Science ®Google Scholar
• Slakter JS, Bochow T, D’Amico DJ, et al. Anecortave acetate (15 milligrams) versus photodynamic therapy for treatment of subfoveal neovascularisation in age-related macular degeneration. Ophthalmology. 2006;113:3–13.
   PubMed Web of Science ®Google Scholar
• Giansanti F, Eandi CM, Virgili G. Submacular surgery for choroidal neovascularisation secondary to age-related macular degeneration. Cochrane Database Syst Rev. 2009;15:CD006931.
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Care Excellence. Macular translocation for age-related macular degeneration: interventional procedures guidance [IPG48]; 2004 Mar [cited 2016 Jun 6]. Available from http://www.nice.org.uk/nicemedia/pdf/IPG048guidance.pdf
   Google Scholar
• Holz FG, Engenhart R, Bellmann C, et al. Stereotactic radiation therapy for subfoveal choroidal neovascularisation secondary to age-related macular degeneration. Front Radiat Ther Oncol. 1997;30:238–246.
   PubMedGoogle Scholar
• Jackson TL, Chakravarthy U, Kaiser PK, et al. Stereotactic radiotherapy for neovascular age-related macular degeneration: 52-week safety and efficacy results of the INTREPID study. Ophthalmology. 2013;120:1893–1900.
   PubMed Web of Science ®Google Scholar
• Jackson TL, Chakravarthy U, Slakter JS, et al. Stereotactic radiotherapy for neovascular age-related macular degeneration: year 2 results of the INTREPID study. Ophthalmology. 2015;122:138–145.
   PubMed Web of Science ®Google Scholar
• Neffendorf JE, Desai R, Wang Y, et al. Stereotactic radiotherapy for wet age-related macular degeneration (STAR): study protocol for a randomised controlled clinical trial. Trials. 2016;17:560.
   PubMed Web of Science ®Google Scholar
• Ruckman J, Green L, Beeson J, et al. 2ʹ-Fluoropyrimidine RNA-based aptamers to the 165-amino acid form of vascular endothelial growth factor (VEGF 165). Inhibition of receptor binding and VEGF-induced vascular permeability through interactions requiring the exon 7-encoded domain. J Biol Chem. 1998;273:20556–20567.
   PubMed Web of Science ®Google Scholar
• Singerman LJ, Masonson H, Patel M, et al. Pegaptanib sodium for neovascular age-related macular degeneration: third-year safety results of the VEGF Inhibition Study in Ocular Neovascularisation (VIISON) trial. Br J Ophthalmol. 2008;92:1606–1611.
   PubMed Web of Science ®Google Scholar
• Sivaprasad S, Laser and Retinal Research Unit, King’s College Hospital, UK. Role of pegaptanib sodium in the treatment of neovascular age-related macular degeneration. Clin Ophthalmol. 2008;2:339–346.
   PubMedGoogle Scholar
• Chakravarthy U, Harding SP, Rogers CA, et al., IVAN Study Investigators. Alternative treatments to inhibit VEGF in age-related choroidal neovascularization: 2-year findings of the IVAN randomized controlled trial. Lancet. 2013;382:1258–1267.
   PubMed Web of Science ®Google Scholar
• Group CR, Martin DF, Maguire MG, et al., The CATT Research Group. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med. 2011;364:1897–1908.
   PubMed Web of Science ®Google Scholar
• Rosenfeld PJ, Brown DM, Heier JS, et al., for the MARINA Study Group. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006;355:1419–1431.
   PubMed Web of Science ®Google Scholar
• Brown DM, Kaiser PK, Michels M, et al., ANCHOR Study Group. Ranibizumab versus veteporfin for neovascular age-related macular degeneration. N Engl J Med. 2006;355:1432–1444.
   PubMed Web of Science ®Google Scholar
• Martin DR, Maguire MG, Fine SL, et al., Comparison of Age-Related Macular Degeneration Treatments Trials (CATT) Research Group. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmology. 2012;119:1388–1398.
   PubMed Web of Science ®Google Scholar
• Holash J, Davis S, Papdopoulos N, et al. VEGF-Trap: a VEGF blocker with potent antitumor effects. Proc Natl Acad Sci USA. 2002;99:11393–11398.
   PubMed Web of Science ®Google Scholar
• Dixon JA, Olver SC, Olson JL, et al. VEGF Trap-Eye for the treatment of neovascular age-related macular degeneration. Expert Opinion Investig Drugs. 2009;18:1573–1580.
   PubMed Web of Science ®Google Scholar
• Semeraro F, Morescalchi F, Duse S, et al. Aflibercept in wet AMD: specific role and optimal use. Drug Des Devel Ther. 2013;7:711–722.
   PubMed Web of Science ®Google Scholar
• Aflibercept: AVE 0005, AVE 005, AVE0005, VEGF Trap – regeneron, VEGF Trap (R1R2), VEGF Trap-Eye. Drugs R D. 2008;9:261–269.
   PubMed Web of Science ®Google Scholar
• Papadopoulos N, Martin J, Ruan Q, et al. Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab. Angiogenesis. 2012;15:171–185.
   PubMed Web of Science ®Google Scholar
• Furfine E, Coppi A, Koehler-Stec EM, et al. Pharmacokinetics and ocular tissue penetration of VEGF trap after intravitreal injections in rabbits. Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO), April-May; Fort Lauderdale, FL; 2006.
   Google Scholar
• Clauss M. Molecular biology of the VEGF and the VEGF receptor family. Semin Thromb Hemost. 2000;26:561–569.
   PubMed Web of Science ®Google Scholar
• Rakic JM, Lambert V, Munaut C, et al. Mice without uPA, tPA or plasminogen genes are resistant to experimental choroidal neovascularization. Invest Ophthalmol Vis Sci. 2003;44:1732–1739.
   PubMed Web of Science ®Google Scholar
• Stewart MQ, Rosenfeld PJ. Predicted biological activity of intravitreal VEGF Trap. Br J Ophthalmol. 2008;92:667–668.
   PubMed Web of Science ®Google Scholar
• Stewart MW. What are the half-lives of ranibizumab and aflibercept (VEGF Trap-eye) in human eyes? Calculations with a mathematical model. Eye Rep. 2011;1:e5.
   Google Scholar
• Bakri SJ, Snyder MR, Reid JM, et al. Pharmacokinetics of intravitreal bevacizumab (Avastin). Ophthalmology. 2007;114:855–859.
   PubMed Web of Science ®Google Scholar
• Bakri SJ, Snyder MR, Reid JM, et al. Pharmacokinetics of intravitreal ranibizumab (Lucentis). Ophthalmology. 2007;114:2179–2182.
   PubMed Web of Science ®Google Scholar
• Schmidt-Erfurth U, Eldem B, Guymer R, et al., The EXCITE Study Group. Efficacy and safety of monthly versus quarterly ranibizumab treatment in neovascular age-related macular degeneration: the EXCITE study. Ophthalmology. 2011;118:831–839.
   PubMed Web of Science ®Google Scholar
• Heier JS, Brown DM, Chong V, et al. Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology. 2012;119:2537–2548.
   PubMed Web of Science ®Google Scholar
• Saishin Y, Saishin Y, Takahashi K, et al. VEGF-TRAP(R1R2) suppresses choroidal neovascularization and VEGF-induced breakdown of the blood retinal barrier. J Cell Physiol. 2003;195:241–248.
   PubMed Web of Science ®Google Scholar
• Nguyen QD, Shah SM, Hafiz G, et al., CLEAR-AMD 1 Study Group. A phase I trial of an IV-administered vascular endothelial growth factor trap for treatment in patients with choroidal neovascularization due to age-related macular degeneration. Ophthalmology. 2006;113:1522.e1–1532.e.14.
   PubMed Web of Science ®Google Scholar
• Nguyen QD, Shah SM, Browning DJ, et al. A phase I study of intravitreal vascular endothelial growth factor trap-eye in patients with neovascular age-related macular degeneration. Ophthalmology. 2009;116:2141–2148.
   PubMed Web of Science ®Google Scholar
• Brown DM, Heier JS, Ciulla T, et al., CLEAR-IT 2 Investigators. Primary endpoint results of a phase II study of vascular endothelial growth factor trap-eye in wet age-related macular degerneration. Ophthalmology. 2011;118:1089–1097.
   PubMed Web of Science ®Google Scholar
• Heier JS, Boyer D, Nguyen QD, et al., CLEAR-IT 2 Investigators. The 1 year results of CLEAR-IT 2, a phase 2 study of vascular endothelial growth factor trap-eye dosed as-needed after 12 week fixed dosing. Ophthalmology. 2011;118:1098–1106.
   PubMed Web of Science ®Google Scholar
• Heier JS, Brown DM, Chong V, et al., VIEW 1 and VIEW 2 Study Groups. Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology. 2012;119:2537–2548.
   PubMed Web of Science ®Google Scholar
• Yuzawa M, Fujita K, Wittrup-Jensen K, et al., VIEW 1 and VIEW 2 Study Groups. Improvement in vision-related function with intravitreal aflibercept: data from phase 3 studies in wet age-related macular degeneration. Ophthalmology. 2015 March;122:571–578.
   PubMed Web of Science ®Google Scholar
• Schmidt-Erfurth U, Kaiser P, Korobelnik JF, et al., VIEW 1 and VIEW 2 Study Groups. Intravitreal aflibercept injection for neovascular age-related macular degeneration: ninety-six week results of the VIEW studies. Ophthalmology. 2014;121:193–201.
   PubMed Web of Science ®Google Scholar
• Regeneron Pharmaceuticals, Inc. Bayer and REgeneron report positive top-line results of two phase 3 studies with VEGF Trap-Eye in wet age-related macular degeneration [press release]. Tarrytown, NY: Regeneron Pharmaceuticals, Inc; 2010 Nov [cited 2016 May 21]; Available from: http:///newsroom.regeneron.com/releasedetail.cfm?releaseid=532099.
   Google Scholar
• Garcia-Layana A, Figueroa MS, Araiz J, et al. Treatment of exudative age-related macular degeneration: focus on aflibercept. Drugs Ageing. 2015;32:797–807.
   PubMed Web of Science ®Google Scholar
• DeCroos F, Reed D, Murtaza K, et al. Treat-and-extend therapy using aflibercept for neovascular age-related macular degeneration: a prospective clinical trial. Am J Ophthalmol. 2017;180:142–150.
   PubMed Web of Science ®Google Scholar
• Ozturk M, Harris ML, Nguyen V, et al. Real-world visual outcomes in patients with neovascular age-related macular degeneration receiving aflibercept at fixed intervals as per UK licence. Clin Exp Ophthalmol. 2017; DOI:10.111/ceo.13085.epub
   Google Scholar
• Ito A, Matsumoto H, Morimoto M, et al. Two-year outcomes of a treat-and-extend regimen using intravitreal aflibercept injections for typical age-related macular degeneration. Ophthalmologica. 2017;238:236–242.
   PubMed Web of Science ®Google Scholar
• Fliney GD, Zukin LM, Hagedorn C. Neovascular age-related macular degeneration disease quiescence with visual acuity stability in a subgroup of patients following PRN treatment. J Ocul Pharmacol Ther. 2017;33:604–609.
   PubMed Web of Science ®Google Scholar
• Mantel I, Niderprim S-A, Gianniou C, et al. Reducing the clinical burden of ranibizumab treatment for neovascular age-related macular degeneration using an individually planned regimen. Br J Ophthalmol. 2014;98:1192–1196.
   PubMed Web of Science ®Google Scholar
• Gianniou C, Dirani A, Ferrini W, et al. Two-year outcome of an observe- and-plan regimen for neovascular age-related macular degeneration: how to alleviate the clinical burden with maintained functional results. Eye. 2015;29:342–349.
   PubMed Web of Science ®Google Scholar
• Parvin P, Zola M, Dirani A, et al. Two-year outcome of an observe-and-plan regimen for neovascular age-related macular degeneration treated with aflibercept. Graefes Arch Clin Exp Ophthalmol. 2017;255:2127–2134.
   PubMed Web of Science ®Google Scholar
• Salwar S, Clearfield E, Soliman MK, et al. Aflibercept for neovascular age-related macular degeneration. Cochrane Database Syst Rev. 2016;2:CD011346.
   PubMedGoogle Scholar
• Lotery A, Griner R, Ferreira A, et al. Real world visual acuity outcomes between ranibizumab and aflibercept in treatment of neovascular AMD in a large US dataset. Eye. 2017;31:1–10.
   Web of Science ®Google Scholar
• Park DH, Sun HJ, Lee SJ. A comparison of responses to intravitreal bevacizumab, ranibizumab, or aflibercept injections for neovascular age-related macular degeneration. Int Ophthalmol. 2017;37:1205–1214.
   PubMed Web of Science ®Google Scholar
• Gasperini J, Fawzi AA, Khondkayran A, et al. Bevacizumab and ranibizumab tachyphylaxis in the treatment of choroidal neovascularisation. Br J Ophthalmol. 2012;96:14–20.
   PubMed Web of Science ®Google Scholar
• Singh RP, Srivastava S, Ehlers JP, et al. A single-arm investigator-initiated study of the efficacy, safety and tolerability of intravitreal aflibercept in subjects with exudative age-related macular degeneration previously treated with ranibizumab or bevacizumab: 6 month interim analysis. Br J Ophthalmol. 2014;98:i22–7.
   PubMed Web of Science ®Google Scholar
• Arcinue CA, Feiyan M, Barteselli G, et al. One year outcomes of aflibercept in recurrent or persistent neovascular age related macular degeneration. Am J Ophthalmol. 2015;159:426–436.
   PubMed Web of Science ®Google Scholar
• Jorstad OK, Faber RT, Moe MC. Two-year functional and anatomical results after converting treatment resistant eyes with exudative age-related macular degeneration to aflibercept in accordance with a treat and extend protocol. Acta Ophthalmol. 2017;95:460–463.
   PubMed Web of Science ®Google Scholar
• Grunwald JE, Daniel E, Huang J, et al. Risk of geographic atrophy in the comparison of age related macular degeneration treatments trials. Ophthalmology. 2014;121:150–161.
   PubMed Web of Science ®Google Scholar
• Ziateva GP, Javitt JC, Shah SN, et al. Comparison of comorbid conditions between neovascular age-related macular degeneration patients and a control cohort in the Medicare population. Retina. 2007;27:1292.
   PubMed Web of Science ®Google Scholar
• Leung KF, Downes SM, Chong V. A retrospective analysis of the effect of subretinal hyper-reflective material and other morphological features of neovascular age-related macular degeneration on visual acuity outcomes in eyes treated with intravitreal aflibercept over one year. Vision. 2018;2:5.
   Google Scholar
• Ores R, Puche N, Querques G, et al. Hyper-reflective subretinal exudative lesions in exudative age-related macular degeneration. Am J Ophthalmol. 2014;158:354–361.
   PubMed Web of Science ®Google Scholar
• Querques G, Kamami-Levy C, Georges A, et al. Appearance of regressing drusen on adaptive optics in age-related macular degeneration. Ophthalmology. 2014;121:611–612.
   PubMed Web of Science ®Google Scholar
• Smithwick E, Stewart MW. Designed Ankyrin Repeat Proteins: A look at their evolving use in medicine with a focus on the treatment of chorioretinal vascular disorders. Antiinflamm Antiallergy Agents Med Chem. 2017;16:33–45.
   PubMedGoogle Scholar
• Brandl C, Grassmann F, Riolfi J, et al. Tapping stem cells to target AMD: challenges and prospects. J Clin Med. 2015;4:281–303.
   Web of Science ®Google Scholar
• Rakoczy EP, Lai CM, Magno AL, et al. Gene therapy with recombinant adeno-associated vectors for neovascular age-related macular degeneration: 1 year follow-up of a phase 1 randomised clinical trial. Lancet. 2015;386:2395–2403.
   PubMed Web of Science ®Google Scholar
• Troutbeck R, Al-Qureshi S, Guymer R. Therapeutic targeting of the complement system in age-related macular degeneration: a review. Clin Exp Ophthalmol. 2012;40:18–26.
   PubMed Web of Science ®Google Scholar
• Brett J, Downes SM. Oxford Eye Hospital clinical images database. Oxford, UK: Oxford Eye Hospital, John Radcliffe Hospital. 2018.
   Google Scholar